BackKontafarma China Holdings Overview
Kontafarma China Holdings Ltd

Kontafarma China Holdings Return on Equity

Latest ROE for Kontafarma China Holdings: -112.81% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-112.81%

Return on Equity

-112.81%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Kontafarma China Holdings (1312.HK) FAQ

Kontafarma China Holdings (1312.HK) currently reports a ROE of -112.81%. That is below the sector sector average of 11.3%. Use the charts on this page to explore Kontafarma China Holdings's ROE history and peer comparisons.

Kontafarma China Holdings's ROE of -112.81% is lower than the its sector sector average of 11.3%. That is roughly 1098.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Kontafarma China Holdings's current -112.81% should be judged against industry norms (sector average: 11.3%) and against 1312.HK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -112.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Kontafarma China Holdings, and consider following 1312.HK for alerts when major investors trade the stock.